DK1937673T3 - Imidazolderivater som hæmmere af tafi-a - Google Patents
Imidazolderivater som hæmmere af tafi-a Download PDFInfo
- Publication number
- DK1937673T3 DK1937673T3 DK06792327.6T DK06792327T DK1937673T3 DK 1937673 T3 DK1937673 T3 DK 1937673T3 DK 06792327 T DK06792327 T DK 06792327T DK 1937673 T3 DK1937673 T3 DK 1937673T3
- Authority
- DK
- Denmark
- Prior art keywords
- ylmethyl
- imidazol
- propionic acid
- amino
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (6)
1. Forbindelse med formel I
(I) og/eller alle stereoisomere former af forbindelsen med formel I og/eller blandinger af disse former i ethvert forhold og/eller fysiologisk forligeligt salt af forbindelsen med formel I, idet U står for -(C1-C4)-alkylen-Het-Z, og idet U og Z tilsammen danner gruppen
og pyridyldelen i gruppen er usubstitueret eller er substitueret med methyl eller ethyl, n står for nul, R står for hydrogenatom eller -(C1-C4)-alkyl, V står for 1) hydrogenatom, 2) - (C1-C3)-alkyl eller 3) fluor, chlor eller brom, W står for - (C1-C3)-alkylen, X står for en aromatisk fem- til trettenleddet heterocyklus, idet heterocyklus er udvalgt af gruppen isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thienopyridin eller thienyl, og heterocyklus er usubstitueret eller er substitueret en, to eller tre gange uafhængigt af hinanden med RI, Y står for 1) -(C3-C6)-cycloalkyl, idet cycloalkyl er usubstitueret eller er substitueret en, to eller tre gange uafhængigt af hinanden med RI, 2) - (C6-C14)-aryl, idet aryl er udvalgt af gruppen indanyl, naphthyl, phenyl eller tetrahydronaphthalenyl, idet aryl er usubstitueret eller er substitueret en, to eller tre gange uafhængigt af hinanden med RI, eller 3) står for heterocyklus, idet heterocyklus er udvalgt af gruppen 2,3-dihydro-benzo[1,4]dioxin, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thienopyridin eller thienyl, og Het er usubstitueret eller er substitueret en, to eller tre gange uafhængigt af hinanden med RI, og RI står for fluor, chlor, brom, - (C1-C4) -alkyl, - (C0-C4)-alkylen-phenyl, -0-CH3, -0-(C1-C4)-alkylen-phenyl, idet phenyl er usubstitueret eller er substitueret en eller to gange med fluor, chlor, brom eller -0-(C1-C4)-alkyl, for - (C3-C6) -cycloalkyl eller -CF3.
2. Forbindelse med formel I ifølge krav 1, kendetegnet ved, at forbindelsen 3-(6-amino-pyridin-3-yl)-2-{1-[5-(5-chlor-thiophen-2-yl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-phenyl-isoxazol-3-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-methoxy-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(5-chlor-thiophen-2-yl)- [1.3.4] thiadiazol-2-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-chlor-phenyl)- [1.3.4] thiadiazol-2-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-trifluormethyl-phenyl)- [1.2.4] oxadiazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(3-trifluormethyl-phenyl)- [1.2.4] oxadiazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-cyclopropyl- [1.3.4] thiadiazol-2-ylmethyl)-lH-imidazol- 4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-phenyl-[1,2,4]oxadiazol-3-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[3-(3,4-dimethoxy-phenyl)- [1.2.4] oxadiazol-5-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)—2 —{1—[3-(4-methoxy-phenyl)- [1.2.4] oxadiazol-5-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)—2—{1-[3-(4'-isopropyl-phenyl)- [1.2.4] oxadiazol-5-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[3-(4'-tert-butyl-phenyl)- [1.2.4] oxadiazol-5-ylmethyl]-lH-imidazol-4-yl}-propionyure, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(3,4-dichlor-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[3-(4-methoxy-phenyl)- [1.2.4] oxadiazol-5-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-phenyl-[1,3,4]thiadiazol-2-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-methoxy-phenyl)- [1.3.4] thiadiazol-2-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)— 2 —{1—[5-(3,5-dimethyl-isoxazol-4-yl)- [1.2.4] oxadiazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-thiophen-2-yl-isoxazol-3-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-(1—{3 —[4-(4-chlor-benzyloxy)-phenyl]-[1,2,4]oxadiazol-5-ylmethyl}-lH-imidazol-4-yl)-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(4-phenyl-5-trifluormethyl-thiophen-2-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-brom-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-p-tolyl-isoxazol-3-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-(1 — {2 —[5-(5-chlor-thiophen-2-yl)-isoxazol-3-yl]-ethyl}-lH-imidazol-4-yl)-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-isobutyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-cyclopentyl- [1.3.4] thiadiazol-2-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-cyclobutyl-[1,3,4]thiadiazol- 2- ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3- (6-amino-pyridin-3-yl)-2-[1-(5-cyclopropyl-isoxazol-3-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-cyclohexyl-isoxazol-3- ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-cyclohexyl-[1,3,4]thiadiazol- 2- ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3- (6-amino-pyridin-3-yl)-2-[1-(5-cyclobutyl-isoxazol-3-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-fluor-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-benzyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-tert-butyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-tert-butyl-2,6-dimethyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(2-chlor-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-sec-butyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-[1-(5-indan-5-yl-isoxazol-3-ylmethyl)-lH-imidazol-4-yl]-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-cyclopentyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-isopropyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-butyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-cyclohexyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)—2—{1—[5—(5,6,7,8-tetrahydro-naphthalen-2-yl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-propyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)-2-{1-[5-(4-phenethyl-phenyl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-pyridin-3-yl)— 2 —{1—[5-(2,3-dihydro- benzo[1,4]dioxin-6-yl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, (S)-3-(6-amino-pyridin-3-yl)-2-{1-[5-(5-chlor-thiophen-2-yl)- isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyreethylester, (R) -3-(6-amino-pyridin-3-yl)-2-{1-[5-(5-chlor-thiophen-2-yl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyreethylester, (S) -3-(6-amino-pyridin-3-yl)-2-{1-[5-(5-chlor-thiophen-2-yl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, (R)-3-(6-amino-pyridin-3-yl)-2-{1-[5-(5-chlor-thiophen-2-yl)-isoxazol-3-ylmethyl]-lH-imidazol-4-yl}-propionsyre, 3-(6-amino-5-methyl-pyridin-3-yl)-2-[1-(5-cyclopropyl- [1,3,4]thiadiazol-2-ylmethyl)-1 H-imidazol-4-yl]-propionsyre,
3. Fremgangsmåde til fremstilling af forbindelsen med formel I ifølge et af kravene 1 eller 2, kendetegnet ved, at man a) omsætter en forbindelse med formel III
(III) idet R, U og V har de i forbindelsen med formel I ifølge krav 1 nævnte betegnelser, med en forbindelse LG-W-X-Y, idet W, X og Y har de i forbindelsen med formel I ifølge krav 1 nævnte betegnelser, og LG er en fraspaltelig gruppe fra rækken -Cl, -Br, -I, -O-tosyl eller -O-mesyl, til en forbindelse med formel I ifølge krav I, idet R ikke er hydrogenatom, eller omsætter forbindelsen med formel I ifølge krav I, idet R ikke er hydrogenatom, ved hjælp af spaltning af esteren til en forbindelse med formel I, idet R betegner hydrogenatom, eller b) opsplitter en ifølge fremgangsmåden a) fremstillet forbindelse med formel I eller et egnet forstadie af formel I, som på basis af sin kemiske struktur optræder i enantiomere former, ved hjælp af saltdannelse med enantiomerrene syrer eller baser, kromatografi på chirale stationærfaser eller derivatisering ved hjælp af chirale, enantiomerrene forbindelser såsom aminosyrer, separation af de således opnåede diastereomerer og fraspaltning af de chirale hjælpegrupper i de rene enantiomerer, eller c) omdanner den ifølge fremgangsmåderne a) eller b) fremstillede forbindelse med formel I enten isoleret i fri form eller i tilfælde af forekomsten af syre eller basiske grupper til fysiologisk forligelige salte.
4. Lægemiddel, kendetegnet ved et aktivt indhold af i det mindste en forbindelse med formel I ifølge et af kravene 1 eller 2 sammen med et farmaceutisk egnet og fysiologisk forligeligt bærestof, tilsætningsstof og/eller andre aktiveller hjælpestoffer.
5. Anvendelse af forbindelsen med formel I ifølge et af kravene 1 eller 2 til fremstilling af et lægemiddel til profylakse, sekundærprævention eller terapi af alle sådanne sygdomme, som er forbundet med tromboser, embolier, hyperkoagulabilitet eller fibrotiske forandringer.
6. Anvendelse ifølge krav 5, kendetegnet ved, at det drejer sig om myokardieinfarkt, Angina pectoris og andre former for akut koronarsyndrom, slagtilfælde, perifere vaskulære sygdomme, dyb venetrombose, lungeemboli, emboliske eller trombotiske hændelser betinget af kardielle arrhytmier, kardiovaskulære hændelser såsom restenose efter revaskularisering og angioplasti og lignende indgreb såsom stentimplantationer og bypass-operationer, eller reduktion af tromboserisikoen efter kirurgiske indgreb såsom ved knæ- og hofteledsoperationer eller om dissemineret intravaskulær koagulation, sepsis og andre intravaskulære hændelser, som er forbundet med en infektion, atherosklerose, diabetes og det metaboliske syndrom og følgerne heraf, tumorvækst og tumormetastasering, betændte og degenerative ledsygdomme såsom rheumatoid artritis og arthrose, forstyrrelser i det hæmostatiske system såsom fibrinaflejringer, fibrotiske forandringer i lungerne såsom kronisk obstruktiv lungesygdom, adult respiratory distress syndrom eller fibrinaflejringer i øjet efter øjenoperationer eller hindring og/eller behandling af ardannelse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005049385A DE102005049385A1 (de) | 2005-10-15 | 2005-10-15 | Imidazolderivate als Inhibitoren von TAFIa |
PCT/EP2006/009500 WO2007045339A1 (de) | 2005-10-15 | 2006-09-30 | Imidazolderivate als inhibitoren von tafi-a |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1937673T3 true DK1937673T3 (da) | 2016-01-25 |
Family
ID=37733974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06792327.6T DK1937673T3 (da) | 2005-10-15 | 2006-09-30 | Imidazolderivater som hæmmere af tafi-a |
Country Status (12)
Country | Link |
---|---|
US (1) | US8044208B2 (da) |
EP (1) | EP1937673B1 (da) |
JP (1) | JP5266053B2 (da) |
CY (1) | CY1117379T1 (da) |
DE (1) | DE102005049385A1 (da) |
DK (1) | DK1937673T3 (da) |
ES (1) | ES2558874T3 (da) |
HU (1) | HUE026577T2 (da) |
PL (1) | PL1937673T3 (da) |
PT (1) | PT1937673E (da) |
SI (1) | SI1937673T1 (da) |
WO (1) | WO2007045339A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2262783A2 (en) * | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
WO2010050525A1 (ja) | 2008-10-29 | 2010-05-06 | 大正製薬株式会社 | TAFIa阻害活性を有する化合物 |
JP5807006B2 (ja) | 2010-03-18 | 2015-11-10 | 第一三共株式会社 | シクロアルキル基で置換されたイミダゾール誘導体 |
KR20130006620A (ko) | 2010-03-18 | 2013-01-17 | 다이이찌 산쿄 가부시키가이샤 | 시클로프로판카르복실산 유도체 |
KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
US9834527B2 (en) * | 2013-06-10 | 2017-12-05 | Sanofi | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals |
CA3165424A1 (en) | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1443173A (zh) * | 2000-08-17 | 2003-09-17 | 辉瑞大药厂 | 作为TAFIa抑制剂的取代的咪唑 |
WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
WO2003061653A1 (en) * | 2002-01-22 | 2003-07-31 | Pfizer Limited | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
-
2005
- 2005-10-15 DE DE102005049385A patent/DE102005049385A1/de not_active Withdrawn
-
2006
- 2006-09-30 HU HUE06792327A patent/HUE026577T2/hu unknown
- 2006-09-30 EP EP06792327.6A patent/EP1937673B1/de not_active Not-in-force
- 2006-09-30 DK DK06792327.6T patent/DK1937673T3/da active
- 2006-09-30 PT PT67923276T patent/PT1937673E/pt unknown
- 2006-09-30 SI SI200632014T patent/SI1937673T1/sl unknown
- 2006-09-30 ES ES06792327.6T patent/ES2558874T3/es active Active
- 2006-09-30 WO PCT/EP2006/009500 patent/WO2007045339A1/de active Application Filing
- 2006-09-30 JP JP2008534894A patent/JP5266053B2/ja not_active Expired - Fee Related
- 2006-09-30 PL PL06792327T patent/PL1937673T3/pl unknown
-
2008
- 2008-04-14 US US12/102,105 patent/US8044208B2/en not_active Expired - Fee Related
-
2016
- 2016-01-20 CY CY20161100053T patent/CY1117379T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP5266053B2 (ja) | 2013-08-21 |
PT1937673E (pt) | 2016-02-08 |
WO2007045339A1 (de) | 2007-04-26 |
PL1937673T3 (pl) | 2016-03-31 |
EP1937673B1 (de) | 2015-10-21 |
US8044208B2 (en) | 2011-10-25 |
US20080262028A1 (en) | 2008-10-23 |
EP1937673A1 (de) | 2008-07-02 |
JP2009511516A (ja) | 2009-03-19 |
HUE026577T2 (hu) | 2016-06-28 |
SI1937673T1 (sl) | 2016-02-29 |
CY1117379T1 (el) | 2017-04-26 |
DE102005049385A1 (de) | 2007-04-19 |
ES2558874T3 (es) | 2016-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1937673T3 (da) | Imidazolderivater som hæmmere af tafi-a | |
ES2299026T3 (es) | Derivados de imidazol en calidad de inhibidores de tafia. | |
CA2623294C (en) | 2-aminoethoxyacetic acid derivatives and their use | |
US9688645B2 (en) | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | |
JP2008074875A (ja) | エンドテリン介在障害治療用のスルホンアミド類 | |
JP2008208143A (ja) | エンドテリン介在障害治療用のスルホンアミド類 | |
JP5249226B2 (ja) | 凝固第IXa因子インヒビターとしての使用のためのイソセリン誘導体 | |
DK2104497T3 (da) | Sulfamidderivater som inhibitorer af tafia | |
JP2010511034A (ja) | 第Xa因子阻害剤としての(R)−5−メチル−4,5−ジヒドロ−ピラゾール−1,5−ジカルボン酸1−[(4−クロロ−フェニル)−アミド]5−{[2−フルオロ−4−(2−オキソ−2H−ピリジン−1−イル)−フェニル]−アミド} | |
JP2008521844A (ja) | 環状イミノカルバメート類およびそれらの使用 | |
CA2448639A1 (en) | Novel heterocyclic derivatives and medicinal use thereof | |
TW200829557A (en) | Tartrate derivatives as inhibitors of coagulation factor IXa | |
KR100854584B1 (ko) | 피리다지논, 피리미돈 또는 피리돈 구조를 포함하는선택적인 트롬빈 억제제 |